Redeye: I-Tech (Q3 Review) - Forecasts Trimmed, Long-Term View Unchanged
Redeye lowers its forecast following softer-than-expected Q3’25 figures. With 10% organic growth, the underlying business continues to perform positively with customer progress and new partnerships announcements in Q4’25. We adjust our short-term estimates and valuation.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/